Toronto-Dominion Bank vs Twist Bioscience Corp — how do they compare? Toronto-Dominion Bank trades at $113.49 (market cap $185.79B), while Twist Bioscience Corp trades at $159.86 (market cap $10.08B). The key difference: Toronto-Dominion Bank is far larger — about 18.4× Twist Bioscience Corp's market cap, and Toronto-Dominion Bank pays a 2.84% dividend while Twist Bioscience Corp pays none. Which is the better fit depends on your goals — on Pluang, investors hold Toronto-Dominion Bank for 84 Days and Twist Bioscience Corp for 27 Days on average.
| TD | TWST | |
|---|---|---|
Market Cap | $185.79B | $10.08B |
Volume | 3,263,867 | 4,229,037 |
Sector | Financials | Health |
52-Week High | $124.80 | $205.00 |
52-Week Low | $78.32 | $25.45 |
Typical Hold Time | 84 Days | 27 Days |
Enterprise Value | $559.06B | $10.01B |
Dividend Yield | 2.84% | — |
Signals from Pluang's Aura AI — not financial advice
TD stock trades at $113.87, down 3.65% on the day, with technical indicators showing bearish momentum. The company reported strong earnings beats in recent quarters with Q2 2026 EPS of $1.98 beating expectations of $1.74. Revenue growth continues with 2025 revenue reaching $61.28B, though cash flow volatility remains a concern with operating cash flow turning negative in 2025. The $10 billion share buyback program and $108 billion Canadian infrastructure commitment signal management confidence.
TD presents a mixed investment case with solid fundamentals offset by technical weakness. The stock offers value with a reasonable P/E of 17.36 and strong analyst support (52.94% buy ratings), but faces headwinds from cash flow volatility and declining profit margins. The current price near support levels may offer entry points for long-term investors attracted to the dividend yield and buyback program.
TWST trades at $155.65, down 6.78% over 24 hours, with a bearish technical signal and negative cash flows. Revenue growth is strong, reaching $377M in 2025, but the company remains unprofitable with a net income margin of -31.66%. Recent news highlights its role in Eli Lilly's AI-driven drug discovery platform, boosting sentiment despite earnings misses.
The outlook is mixed: analyst consensus is bullish with a $145.20 price target, but high valuation multiples and persistent losses pose risks. Investment opportunity hinges on AI partnerships driving future profitability, while execution risks and cash burn require careful monitoring.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Toronto-Dominion is one of Canada's two largest banks and operates three business segments: Canadian retail banking, U.S. retail banking, and wholesale banking. The bank's U.S. operations span from Maine to Florida, with a strong presence in the Northeast. It also has a 13% ownership stake in Charles Schwab.
Read more on TD →Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →